Yes, metformin works for prediabetes. In the landmark Diabetes Prevention Program (DPP), metformin reduced progression to type 2 diabetes by 31 percent over 2.8 years of follow-up. However, intensive lifestyle change outperformed it in the same trial, cutting risk by 58 percent. Metformin is best viewed as a supporting tool for specific high-risk groups rather than a first-line replacement for diet and exercise.
What Metformin Does in the Body
Metformin is a biguanide medication that lowers blood glucose through three main mechanisms:
- Reduces liver glucose production (its primary action, by suppressing hepatic gluconeogenesis)
- Increases insulin sensitivity in muscle and fat tissue
- Slows glucose absorption from the intestines
Importantly, metformin does not cause the pancreas to release more insulin. That is why it rarely causes hypoglycemia on its own and is considered one of the safer glucose-lowering medications.
The Diabetes Prevention Program Evidence
The Diabetes Prevention Program remains the most important study ever conducted on prediabetes treatment. Published in the New England Journal of Medicine in 2002, it randomized 3,234 adults with prediabetes (elevated fasting glucose and impaired glucose tolerance) into three arms:
| Treatment Arm | Intervention | Risk Reduction vs. Placebo |
|---|---|---|
| Placebo | Standard lifestyle advice | Reference |
| Metformin | 850 mg twice daily + standard advice | 31% |
| Intensive lifestyle | 7% weight loss + 150 min/wk exercise | 58% |
The benefit of metformin was not uniform across all participants. It worked dramatically better in certain subgroups:
- Adults under age 60: larger benefit
- BMI of 35 or higher: risk reduction approached that of lifestyle change
- Women with prior gestational diabetes: metformin cut progression by 50 percent
- Adults over 60: minimal benefit from metformin alone
Long-Term Follow-Up: The DPPOS Study
The Diabetes Prevention Program Outcomes Study (DPPOS) followed the original cohort for 15 additional years. The key findings:
- The risk reduction persisted for more than a decade
- Metformin participants maintained about a 18 percent lower cumulative diabetes incidence at 15 years
- Microvascular complications (eye, kidney, nerve damage) were reduced in both treatment arms
- Metformin use correlated with modestly lower rates of cancer and cardiovascular events, though these were secondary findings
Who Should Consider Metformin for Prediabetes
The American Diabetes Association’s Standards of Care explicitly support considering metformin for prevention in people with prediabetes who meet any of the following criteria:
- Age under 60
- BMI of 35 kg/m² or higher
- Prior history of gestational diabetes
- Rising A1C despite lifestyle efforts
- Metabolic syndrome or strong family history of type 2 diabetes
Metformin is generally not first-line for people over 60 without these risk factors, because the benefit is smaller and the risk of B12 deficiency and GI side effects may outweigh it.
Dosing Ranges (General Reference)
Dosing is always individualized by a physician, but the ranges studied in the DPP and used in clinical practice include:
| Formulation | Typical Range Studied | Notes |
|---|---|---|
| Immediate-release | 500 mg once daily up to 850 mg twice daily | Used in the original DPP |
| Extended-release (XR) | 500 mg once daily up to 2000 mg once daily | Fewer GI side effects |
Important: These are reference ranges from published trials. Do not self-dose. Starting doses are usually low and increased gradually to minimize side effects. Your physician will adjust based on your kidney function, tolerance, and response.
Side Effects and Risks
Common (and usually manageable)
- Gastrointestinal: nausea, diarrhea, abdominal cramping, metallic taste — affects 20 to 30 percent of users, especially during the first 2 to 4 weeks
- Decreased appetite: often experienced as a benefit
Long-term considerations
- Vitamin B12 deficiency: affects up to 20 percent of long-term users. Annual B12 monitoring is recommended after 4 to 5 years
- Kidney function monitoring: required because metformin is cleared by the kidneys
Rare but serious
- Lactic acidosis: very rare, almost always in people with severe kidney or liver disease. Modern eGFR cutoffs (avoid if under 30 mL/min/1.73m²) have made this nearly a non-issue
Lifestyle vs. Medication: A Head-to-Head Comparison
| Factor | Lifestyle Change | Metformin |
|---|---|---|
| Risk reduction (DPP) | 58% | 31% |
| Cost | Low (food, shoes, time) | Low (generic, $4–$25/mo) |
| Side effects | Rare (soreness) | GI, possible B12 loss |
| Weight effect | Loss (target 5–7%) | Modest loss (2–3 kg) |
| Cardiovascular benefit | Yes | Possibly |
| Reverses underlying insulin resistance | Yes | Partially |
| Requires sustained effort | Yes | Low effort (one pill) |
The punchline: lifestyle works almost twice as well when done consistently. Medication works when you take it. For most people, the answer is not “either or” but “both” — with lifestyle as the foundation and metformin as a targeted tool when appropriate.
How Metformin Fits Into a Complete Prediabetes Plan
Even if you start metformin, the core work of reversing prediabetes still happens outside the pharmacy:
- Diet: A whole-food, lower-carbohydrate eating pattern addresses the underlying insulin resistance. See our prediabetes diet guide.
- Movement: 150 minutes of moderate activity per week improves insulin sensitivity by 20 to 40 percent.
- Weight loss: 5 to 7 percent of body weight is the DPP threshold.
- Sleep and stress management: both directly influence insulin sensitivity.
- Monitoring: retest A1C every 6 months. Explore our A1C levels hub for what to track.
What About Other Medications?
Metformin is the most-studied, but not the only option being investigated for prediabetes. Pioglitazone, acarbose, and GLP-1 receptor agonists have all shown diabetes prevention effects in clinical trials. However, none carry the decades of safety data and low-cost availability that metformin does, and most are not routinely used for prediabetes in general practice.
Supplements like berberine, inositol, and chromium are also discussed in this space, though evidence is much weaker. Read our overview of supplements for prediabetes for what the research actually shows.
When Metformin Might Not Be Right
- eGFR below 30 mL/min/1.73m² (kidney function contraindication)
- Severe liver disease
- Active alcohol use disorder
- Acute illness with dehydration
- Upcoming surgery or iodinated contrast imaging (temporary hold)
- Intolerable GI side effects after trialing the extended-release formulation
The Bottom Line
Metformin reduces the risk of progressing from prediabetes to type 2 diabetes by about 31 percent — real, sustained, and backed by the strongest trial in the field. But lifestyle change nearly doubles that effect, with no side effects and broader health benefits. The smart approach for most people is to make lifestyle change the foundation, and add metformin only if you are high risk (under 60, BMI 35+, or prior gestational diabetes), or if your A1C continues to rise despite consistent effort. Always make this decision with your physician, not alone.
